false
0001580149
0001580149
2024-03-01
2024-03-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
March 1, 2024
BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Nevada |
|
001-39015 |
|
46-2510769 |
| (State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
680 W Nye Lane Suite 201
Carson City, NV |
|
89703 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(775) 888-3162
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since
Last Report)
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Class A Common Stock, par value $0.0001 per share |
BIVI |
The Nasdaq Stock Market, LLC |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether
the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On March 1, 2024, BioVie Inc.
(the “Company”) issued a press release announcing the presentation of “Improvement of Non-Motor Symptoms with NE3107
Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study” and “Clinical
Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s Disease”
at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 in Lisbon, Portugal.
The Company is filing a copy of the press release,
which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements,
which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,”
“plan,” “believe,” “seek,” “estimate,” “will,” “project” or words
of similar meaning. In this report, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition
and function among study participants and topline data from the NE3107 trial. Although the Company believes such forward-looking statements
are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially
from those expressed or implied by the statements herein due to certain risks, including but are not limited to, the Company’s ability
to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations
that could impair the Company’s ability to pay future dividends, the Company’s ability to complete the Company’s
pre-clinical or clinical studies and to obtain approval for the Company’s product candidates, the Company’s ability
to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional
risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports
filed by the Company with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K and annual
reports on Form 10-K. The Company does not undertake any duty to update any statements contained herein (including any forward-looking
statements), except as required by law.
| Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated March 1, 2024. |
| 104 |
|
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: March 1, 2024
| |
BIOVIE INC. |
| |
|
|
| |
By: |
/s/ Joanne Wendy Kim |
| |
Name: |
Joanne Wendy Kim |
| |
Title: |
Chief Financial Officer |
BioVie’s NE3107 Demonstrates Potential
Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for
Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases
2024
Data
from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor
symptoms and motor control while placebo-treated patients worsened
Data from Phase 3 trial in mild to moderate
Alzheimer’s Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased
neurocognitive decline and diseases of aging
Carson City NV, March 1, 2024 – BioVie Inc., (NASDAQ:
BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment
of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International
Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.
Improvements in non-motor symptoms correlated with improvements
in motor symptoms for Parkinson’s Disease patients
The presentation Improvement of Non-Motor Symptoms with NE3107 Adjunctive
to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study will be presented at 15:10
GMT on March 9, 2024 and suggest improvements of NE3107-treated patients with non-motor symptoms. These findings complement previously
reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity
of NE3107 that is consistent with data from animal models.
NE3107-treated patients experienced a significant improvement of -2.4
points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced
a worsening of +1.0 points (p=0.0159). Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.
NMSS
changes for NE3107-treated patients were driven by improvements of -0.87 in fatigue/lack of energy (p= 0.0005) and improvement of -2.91
on the urge to move legs/restlessness in legs (p=0.0036). Placebo patients saw no significant change of -0.39 on fatigue (p=0.1242) and
-0.71 on leg restlessness (p=0.5141).
The new data on non-motor improvements complements previously presented
data1 showing NE3107-treated patients saw a 3+ points advantage compared to placebo on the Part 3 (motor) score of the Motor
Disease Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In patients younger than 70 years old, the advantage was
over 6 points. Furthermore, 26% of NE3107-treated patients experienced improvement in their ability to move, having Part 3 scores prior
to their first morning dose of carbidopa/levodopa that were equal to or better than Part 3 scores associated with their being in the
“on” state after carbidopa/levodopa treatment at the start of the study, whereas none of the placebo patients
had the similarly improved morning Part 3 scores. The difference was statistically significant (p=0.046).
“These data suggest that NE3107 as adjunct therapy to levodopa
may hold promise in ameliorating specific non-motor symptoms of Parkinson’s Disease, particularly in sleep/fatigue and restlessness
of the legs,” stated Joseph Palumbo, BioVie’s Chief Medical Officer. “These findings extend previously reported improvement
in motor symptoms with NE3107 and demonstrate potential intrinsic and levodopa-enhancing activity of NE3107 that is consistent with data
from animal models and support further clinical investigation of NE3107 in late-phase trials.”
Possible physiological realignment in Alzheimer’s Disease
The presentation Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled
Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s Disease will be presented at 14:50 GMT on March 8, 2024
reconfirms topline cognitive and functional data previously presented and will provide additional biomarker data and analyses.
The NM101 Trial enrolled 439 patients through 39 sites. The Company
previously reported that upon trial completion, significant deviation from protocol and Good Clinical Practice violations were found at
15 sites, causing the Company to exclude all patients from these sites. After these exclusions and other exclusions per the statistical
analysis plan, 57 patients in the Per-Protocol population were verified to have taken study drug from pharmacokinetics data and completed
the full duration of the trial. Baseline and completion data were available for 50 subjects (NE3107, n=24 and placebo, n=26; 7 subjects
randomized to placebo discontinued before day 150), and DNA methylation data were available for 33 subjects in this cohort.
Due to the exclusion of data from so many sites the trial missed statistical
significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared
to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS,
+1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL.2
| 1 | A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial
With NE3107 Adjunctive to Carbidopa/Levodopa in Patients With Parkinson’s Disease. Presented at the 2023 International Congress
of Parkinson’s Disease and Movement Disorders, August 27-31, 2023 in Copenhagen, Denmark |
| 2 | ADAS-Cog12 = 12-item cognitive subscale of the Alzheimer’s Disease
Assessment Scale (lower is improvement); ADCOMS = Alzheimer’s Disease Composite Score (lower is improvement); ADCS-ADL = Alzheimer’s
Disease Cooperative Study-Activities of Daily Living (higher is improvement); ADCS-CGIC = Alzheimer’s Disease Cooperative Study-Clinical
Global Impression of Change (lower is improvement); CDR-SB = Clinical Dementia Rating, Sum of Boxes (lower is improvement), MMSE = Mini
Mental State Examination (higher is improvement). |
Significant improvements for NE3107-treated patients vs. placebo were
observed for biological age deceleration (-3.87 years, p=0.012), fasting glucose levels (-8.5 mg/dL, p=0.036), cholesterol (-15 mg/dL,
p=0.049), HOMA2 beta cell function (+12.4%, p=0.040), HOMA2 Insulin Sensitivity (+1.95%, p=0.018), and MCP1 (-90.5 pg/mL, p=0.007). Trending
improvements in HOMA2 Insulin Resistance of -0.020 (p=0.0.063) were also observed.
A statistical technique called Principal Component Analysis3
identified neurological assessments and biological age deceleration as the two “principal components” that maximally
explained the data across the large set of variables collected. Among NE3107-treated patients, correlations of neurological assessments
and biological age deceleration with improved metabolic and glycemic control, improved neuropsychiatric indices, and levels of
chemokines associated with microglial attraction to and digestion of Aβ plaques. Among placebo patients, neurological assessments
and biological age deceleration were correlated with increased metabolic inflammatory measures, M1 to M2 transition, and plaque phagocytosis.
“We previously reported that NE3107 appeared to decrease metabolic
inflammation-driven systems dysregulation,” stated Chris Reading, BioVie’s Senior Vice President of Alzheimer’s Disease
Programs. “Principal component analyses, divergent correlations, and epigenetic analysis suggest that metabolic inflammation may
be a driver of biological aging and AD, and that NE3107 might have the potential to realign physiological processes consistent with decreased
neurocognitive decline and diseases of aging.”
“The data being presented reinforce our confidence in the potential
of NE3107 to have a meaningful impact on core symptoms of both Alzheimer’s disease and Parkinson’s disease,” stated Cuong Do, BioVie’s
President and CEO. “These findings add to the growing body of evidence supporting our hypothesis that by selectively modulating inflammation
and enhancing insulin sensitivity in the brain, NE3107 could offer benefits in slowing disease progression and improving the lives of
patients living with these devastating conditions.”
About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage
company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling)
that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth
and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company conducted and reported efficacy data
from its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild
to moderate Alzheimer’s disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated
patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease (CTAD)
annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s
disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer’s and Parkinson’s Disease and Related
Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms
and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated
with levodopa alone, and no drug-related adverse events. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous
infusion terlipressin), with U.S. Food and Drug Administration (FDA) Fast Track status, is being evaluated and discussed with guidance
received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis.
The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information,
visit http://www.bioviepharma.com/.
| 3 | Principal component analysis is a statistical method for identifying/combining
separate variables to a few “principal components” that maximally explain the variance of all the underlying variables. In
the process, the method provides an approximation of the original data represented by the many individual variables using only a few major
components. |
Forward-Looking Statements
This press release contains forward-looking
statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,”
“plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar
meaning. In this press release, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition
and function among study participants and topline data from the NE3107 trial. Although BioVie Inc. believes such forward-looking statements
are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially
from those expressed or implied by the statements herein due to the Company’s ability to successfully raise sufficient capital on reasonable
terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends,
our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability
to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional
risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed
by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc.
does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by
law.
For Investor Relations Inquiries:
Contact:
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
For Media Inquires
Melyssa Weible
Managing Partner, Elixir Health Public Relations
Ph: +1 201-723-5705
mweible@elixirhealthpr.com
v3.24.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
BioVie (NASDAQ:BIVI)
過去 株価チャート
から 1 2025 まで 2 2025
BioVie (NASDAQ:BIVI)
過去 株価チャート
から 2 2024 まで 2 2025
